A Study of Chidamide With AZA in MRD Positive AML After Transplant
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high
heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is still the primary treatment option for patients with AML and
the most effective method for radical treatment of AML.Despite considerable progress in
allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant
relapse remains the leading cause of death in patients with AML.